BACKGROUND: Current hypertension management guidelines do not recommend drug treatment in subjects with blood pressure (BP) in the high-normal range due to the risk of side effects of the currently available antihypertensive agents that overcomes the possible benefit. Nutraceuticals are free from relevant side effects and could be a valuable strategy for the treatment of these patients. AIM: The objective of this study was to compare the efficacy of two nutraceutical compositions given by the combination of policosanol, red yeast rice extract, berberine, folic acid and coenzyme Q(10) with or without Orthosiphon stamineus in lowering the BP and lipid profile. METHODS:Thirty patients with grade 1 essential hypertension and low cardiovascular risk were analysed. At the end of a run-in period, patients were divided into two study arms and assigned to receive the nutraceutical combination with and without Orthosiphon stamineus. All participants underwent 24-hour ambulatory BP monitoring at the end of the run-in period and of the 4-week treatment with each of the two different nutraceutical combinations. RESULTS: In patients treated with Orthosiphon stamineus a significant reduction of mean 24-hour systolic and diastolic BP levels compared with baseline values was registered and the smoothness index calculated for systolic and diastolic BP showed a more reliable and homogeneous effect on BP over 24 hours. In contrast, nutraceutical treatment without Orthosiphon stamineus was not associated with a significant reduction of BP. CONCLUSIONS: Our results show that the addition of Orthosiphon stamineus to the combination of nutraceuticals confers an antihypertensive effect that allows a surprisingly effective 24-hour BP control in hypertensive patients.
RCT Entities:
BACKGROUND: Current hypertension management guidelines do not recommend drug treatment in subjects with blood pressure (BP) in the high-normal range due to the risk of side effects of the currently available antihypertensive agents that overcomes the possible benefit. Nutraceuticals are free from relevant side effects and could be a valuable strategy for the treatment of these patients. AIM: The objective of this study was to compare the efficacy of two nutraceutical compositions given by the combination of policosanol, red yeastrice extract, berberine, folic acid and coenzyme Q(10) with or without Orthosiphon stamineus in lowering the BP and lipid profile. METHODS: Thirty patients with grade 1 essential hypertension and low cardiovascular risk were analysed. At the end of a run-in period, patients were divided into two study arms and assigned to receive the nutraceutical combination with and without Orthosiphon stamineus. All participants underwent 24-hour ambulatory BP monitoring at the end of the run-in period and of the 4-week treatment with each of the two different nutraceutical combinations. RESULTS: In patients treated with Orthosiphon stamineus a significant reduction of mean 24-hour systolic and diastolic BP levels compared with baseline values was registered and the smoothness index calculated for systolic and diastolic BP showed a more reliable and homogeneous effect on BP over 24 hours. In contrast, nutraceutical treatment without Orthosiphon stamineus was not associated with a significant reduction of BP. CONCLUSIONS: Our results show that the addition of Orthosiphon stamineus to the combination of nutraceuticals confers an antihypertensive effect that allows a surprisingly effective 24-hour BP control in hypertensivepatients.
Authors: D Rizzoni; M L Muiesan; M Salvetti; M Castellano; G Bettoni; C Monteduro; C Corbellini; E Porteri; D Guelfi; E A Rosei Journal: J Hypertens Date: 2001-04 Impact factor: 4.844
Authors: C Giannattasio; B M Cattaneo; A A Mangoni; S Carugo; M L Stella; M Failla; S Trazzi; R Sega; G Grassi; G Mancia Journal: J Hypertens Date: 1995-02 Impact factor: 4.844
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Paolo Verdecchia; Jan A Staessen; Fabio Angeli; Giovanni de Simone; Augusto Achilli; Antonello Ganau; Gianfrancesco Mureddu; Sergio Pede; Aldo P Maggioni; Donata Lucci; Gianpaolo Reboldi Journal: Lancet Date: 2009-08-15 Impact factor: 79.321
Authors: F Pelliccia; V Pasceri; G Marazzi; A Arrivi; L Cacciotti; G Pannarale; G Speciale; C Greco; C Gaudio Journal: J Hum Hypertens Date: 2017-04-27 Impact factor: 3.012
Authors: Maisa Gomes da Silva; Sara Léa Fortes Barbosa; Diego Santos Silva; Isadora Basílio Meneses Bezerra; Érika Alves Bezerra; Angélica Gomes Coelho; Ilmara Cecília Pinheiro da Silva Morais; Luis Mário Rezende-Júnior; Iolanda Souza do Carmo; José de Sousa Lima-Neto; Simón Gabriel Comerma-Steffensen; Antônia Maria das Graças Lopes Citó; Daniel Dias Rufino Arcanjo Journal: Evid Based Complement Alternat Med Date: 2022-06-20 Impact factor: 2.650